top of page



The ambition of Cancer Campus®: to become an international reference site for innovation in cancer research

Cancer Campus is an association under the French law of 1901 that currently has eight members: Gustave Roussy, the APHP, the University of Paris-Saclay, the Val-de-Marne Chamber of Commerce and Industry, and local authorities. The objective of Cancer Campus is to develop a health biocluster dedicated to the fight against cancer in Villejuif (Val-de-Marne) around Gustave Roussy. This project includes a dimension focused on innovation for the benefit of patients and an economic dimension.

Our ambition is to bring together research, care, training, companies and patient associations on the same site. Cancer Campus brings together all these public and private players and is a place for exchanges and collaboration to ensure a dynamic within the ecosystem.

Within an internationally recognized academic and clinical environment, we facilitate the reception and development of companies in the health sector (biotech, medtech, e-health, service sector companies, etc.).

The fight against cancer: a public health issue

Cancer is a major public health problem. Since 2004, cancer has become the leading cause of death among adults in France. According to the National Cancer Institute (INCa), the number of new cancer cases for 2018 in metropolitan France is estimated at 382,000 (204,600 in men and 177,400 in women). For the past 30 years, the overall number of new cancer cases in France has been increasing every year. This is mainly due to the aging of the population and the improvement of diagnostic methods.

The number of cancer deaths in France in 2018 is estimated at 157,400 ( 89,600 men and 67,800 women). However, overall, survival is progressing and in France is one of the highest in Europe.

In France, the fight against cancer has been structured since 2003 around national plans, supported at the highest level of government by the Presidents of the Republic, aiming to mobilize public health actors around prevention, screening, organization of care, research, support for patients and their families, etc.
support for patients and their families, and post-cancer care. Since that date, three cancer plans led by INCa have been implemented until 2019.

Cancer Plan 1 (2003-2007)

Launched on March 24, 2003, the 2003-2007 Cancer Plan gave a decisive impetus to the fight against cancer in France and to the care of patients.

The Plan has made it possible to reduce tobacco consumption, thanks to a comprehensive anti-smoking strategy combining price increases, a ban on sales to people under the age of 16, information campaigns and actions targeted at young people and women, and the development of cessation aids.
development of smoking cessation aids.

The organized breast cancer screening program was generalized in 2004, while the organized colorectal cancer screening program was tested from 2002 to 2007 in 23 pilot departments.

Quality criteria defining the minimum standard of care were established, and health care institutions had to meet these criteria in order to be authorized to treat cancer patients (in surgery, radiotherapy and chemotherapy).

A new dynamic has been created in cancer research and the 7 cancéropôles have been set up to coordinate research in the regions.

By creating INCa in 2005, the State has also created a health and scientific agency responsible for coordinating actions to fight cancer.

The Cancer Plan 2 (2009-2013)

The 2009-2013 Cancer Plan is structured around five main areas (Research, Observation, Prevention-Screening, Care, Living during and after cancer), 30 measures and 118 actions.

Three cross-cutting themes have also been incorporated into the Plan's strategy.

They aimed to :

  • To take better account of health inequalities to ensure greater equity and effectiveness in all cancer control measures;

  • Stimulate the analysis and consideration of individual and environmental factors to personalize care before, during and after the disease;

  • To strengthen the role of the treating physician at all stages of treatment, in order to improve life during and after the disease.


The Plan has worked to strengthen the quality and safety of care throughout the country. Organizations have been adapted for the care of children with cancer, elderly patients and people with rare cancers. Access to personalized medicine and participation in clinical trials have also progressed. The Plan has also embarked on new avenues to support therapeutic innovations and advance research, particularly in the field of cancer genomics. In 2009, the organized colorectal cancer screening program was extended to the entire country.

In order to ensure continuity in patient care, personalized care and post-cancer programs were tested. However, coordination between hospital teams and community workers, in particular attending physicians, needs to be strengthened. An approach to early detection of social and support needs has been implemented. However, the impact of the disease and its treatment on social and professional life still needs to be taken into account. Efforts must also be continued to better understand the inequalities in the face of cancer and to act more effectively to reduce them.

The 2009-2013 Cancer Plan was evaluated by the French High Council for Public Health (HCSP) in 2014, as part of the evaluation of ten years of cancer control.

The Cancer Plan 3 (2014-2019)

Initiated in January 2014, the third Cancer Plan was completed by the end of 2019, with nearly 90% of the set objectives met.

  • reducing inequalities and lost opportunities, a priority of the cancer plan

  • meeting the needs of children, adolescents and young adults with cancer

This Cancer Plan has made it possible to translate and support the mobilization of an entire community of caregivers, researchers, prevention workers, and also social and education professionals who work on a daily basis to serve patients and the population.


With the major priority of reducing inequalities and loss of opportunity in the face of cancer, the Plan has also paid particular attention to the needs of children, adolescents and young adults with cancer, in order to improve access to innovation and the quality of care, as well as support for children and their families during and after the disease.

The ten-year cancer control strategy 2021-2030

As the third cancer plan drew to a close, the law of March 8, 2019, entrusted INCa with the mission of "proposing, in coordination with research organizations, public and private cancer operators, healthcare professionals, users of the healthcare system and other people concerned, a ten-year strategy to fight cancer, to be determined by decree".

By following up on the successive cancer plans, the ten-year strategy continues the collective mobilization established around the fight against cancer.


This strategy is based on four priorities:
1. Improving prevention ;
2. Limiting sequelae and improving quality of life;
3. To fight against cancers with a poor prognosis;
4. Ensure that progress benefits everyone.

Launch of the strategy.

On the occasion of World Cancer Day, this Thursday, February 4, 2021, the President of the Republic unveiled the ten-year strategy to fight cancer 2021-2030. Ambitious, with new budgetary means, this strategy aims to significantly reduce the burden of cancer in the daily lives of French people. The overall funding is nearly 1.74 billion euros, an increase of nearly 20% compared to the previous Cancer Plan, including additional funding of 284 million euros for the next 5 years. This funding is provided by the Ministry of Research, by the ONDAM (National Health Insurance Expenditure Target) and by the mobilization of part of the Institute's own funds up to 57 million euros.

The Institute, charged by the law of March 8, 2019 with ensuring its implementation, will deploy, starting this year, 65 new actions to serve the French of the more than 240 it contains.

European plan to defeat cancer

The European Union considers cancer to be one of the main public health issues in its member countries. Since 2003, the various decision-making bodies have implemented and adopted numerous recommendations and actions to support the fight against cancer.


The European Plan to Overcome Cancer is a key health priority of the European Commission and a key element for a strong European Health Union. Based on new technologies, research and innovation, the cancer plan sets out a new EU approach to cancer prevention, treatment and care. It will address the whole spectrum of disease management, from prevention to quality of life for cancer patients and survivors, focusing on those measures where the EU can bring the greatest added value.

Notre équipe

The team

Sylvain Ducroz.jpg



  • Grey LinkedIn Icon

President of Cancer Campus

photo Nouzha .jpg




  • Grey LinkedIn Icon

Executive Director




  • Grey LinkedIn Icon

Project Manager

Need more info ? Contact us

If you need assistance, please do not hesitate to contact us.

bottom of page